Recently, Jiangsu Pulai Pharmaceutical Biotechnology Co., Ltd. independently developed a Class 1 innovative drug—Pexiganan Spray—which was officially approved for market launch by the National Medical Products Administration. Peceleganan spray is a topical antibacterial medication, indicated for treating secondary wound infections from first- or second-degree minor burns caused by Staphylococcus epidermidis, Staphylococcus hemolyticus, or Acinetobacter baumannii. The launch of this drug offers patients a new treatment option.
Peceleganan is a recently approved Class 1 innovative drug, generic name Peceleganan Spray, and brand name Puyike. It is mainly used to treat burn wound infections caused by specific bacteria
Basic drug information and approval status
●Drug Name and Nature: Peceleganan Spray (brand name: Puyike ®) is a topical peptide antibacterial drug, classified as a national Class 1 innovative drug.
Peceleganan
●Approval date and institution: The drug was approved for market launch by the National Medical Products Administration (NMPA) of China in June 2026.
● Indications: According to approval by the National Medical Products Administration, this drug is indicated for the treatment of secondary wound infections from Grade I or second-degree burns caused by Staphylococcus epidermidis, Staphylococcus Haemolyticus, and Acinetobacter baumannii
The innovation and significance of the drug
● Global First: Pérecanam is the world's first approved "Canan-class" antimicrobial peptide drug, marking a breakthrough in drug development from zero to one.
●Brand New Mechanism of Action: It employs a brand-new physical sterilization mechanism that rapidly kills bacteria by precisely attacking and disrupting bacterial cell membranes, rather than traditional chemical metabolic interference pathways. This mechanism makes it difficult for bacteria to develop resistance, and it is effective against various resistant bacteria, including "superbugs."
●Clinical Value: The launch of this drug provides a new and highly effective treatment option for patients with secondary wound infections such as burns and scalds, especially showing strong killing effects for clinically challenging infections like Acinetobacter baumannii, and promoting wound healing
R&D background and related impact
· R&D company: Peilai Jiannan is independently developed by Pulai Pharmaceutical (Jiangsu) Co., Ltd. (also known as Jiangsu Pulai Pharmaceutical Biotechnology Co., Ltd.).
· R&D history: This drug was developed from scratch on the company's proprietary antimicrobial peptide platform. It first applied for clinical trials in 2014 and was approved for market launch in December 2024, with a R&D cycle exceeding ten years.
· Industry significance: This drug is the second national Class 1 innovative drug approved by Wuxi City (Jiangyin City) in Jiangsu Province in 2026. With this, Wuxi has accumulated five Class 1 innovative drugs approved, covering three major fields: chemical drugs, biological products, and traditional Chinese medicine
Mechanism of action
According to publicly available information from Pulai Pharma, Pélaicanam spray is a non-antibiotic antibacterial drug, and its sterilization mechanism applies the "cell membrane differentiation mechanism" theory:
Under the influence of electrostatic attraction, positively charged peptides diffuse directionally toward the bacterial surface and cross the cell walls of Gram-positive and Gram-negative bacteria.
Under the combined action of electrostatic attraction and transmembrane negative potential, the peptide is attracted by the cytoplasmic membrane and covers the surface of the bacterial cell membrane. During this process, the peptides are induced by the hydrophobic environment of bacterial cell membranes to form amphiphilic α-helical structures.
Subsequently, the hydrophobic groups on the peptide surface interact with the fatty acid hydrophobic components of the cytoplasmic membrane phospholipids, causing the peptide to flip into the hydrophobic core of the cytoplasmic membrane. A large number of peptide molecules flip over, disrupting the surface tension of the lipid bilayer and undermining membrane stability.
At critical peptide concentrations, cytoplasmic membranes will leak or break down, ultimately leading to bacterial death.
Wu Xi Further Pharmaceutical Co.,Ltd
Main Products
Palmitoylethanolamide(PEA) Micro (CAS 544-31-0)
Spermidine trihydrochloride(CAS 334-50-9)
Pterostilbene(CAS 537-42-8)
Luteolin (CAS 491-70-3)
Voglibose (CAS 83480-29-9) JP GMP
Mailbox:wuxifurther@gmail.com
Whatsapp:+86 18036885286
